TWi successfully launches generic Fenofibric Acid DR Capsules in TWi label

July 2, 2020 . TWi Pharmaceuticals, Inc. announced the official launch of Fenofibric Acid DR Capsules 45mg and 135mg (equivalent to Trilipix®) via its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc.  Product is available for immediate shipment.

Fenofibric Acid DR Capsules are indicated as adjunctive therapy to diet to reduce triglycerides (TG) in patients with severe hypertriglyceridemia, to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia or mixed dyslipidemia. According to IQVIA data, the total sales of Fenofibric Acid DR Capsules in the US were approximately US $31 million for the 12 months ended May 2020.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit